Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to ...

GeneDx was teetering. The genetic testing company had laid off 33% of its staff, shares were down 90% from a year prior, and ...

UnitedHealthcare CEO Brian Thompson was shot and killed in Midtown Manhattan on Wednesday morning, according to media reports ...

Atea Pharmaceuticals reported positive Phase 2 trial results for its hepatitis C combination therapy of bemnifosbuvir and ...

The market for first-generation weight loss treatments has been dominated by two major players, Eli Lilly and Novo Nordisk.

GSK partners with Duality Biologics in a $30 million upfront deal, potentially worth $975 million, for access to a ...

Versant is out with its third obesity biotech of the year, leading an €80 million Series A for Antag Therapeutics, a Danish ...

Eli Lilly has removed the commonly used clinical measure of body mass index from the FDA label for its weight loss drug ...

Ipsen has inked yet another licensing deal in an effort to bolster its cancer pipeline, this time for a preclinical T cell ...

The SEC said Tuesday that it settled charges filed against Kiromic Biopharma, a tiny immuno-oncology startup based in Texas, ...

Relay Therapeutics licenses lirafugratinib to Elevar Therapeutics for $75m upfront and milestone payments, with potential ...

Coherus BioSciences' stock surged on Tuesday after the company announced plans to sell off the last biosimilar in its ...